- Home
- LRMR vs RDIB Comparison
LRMR vs RDIB Comparison
Compare LRMR & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- RDIB
- Stock Information
- Founded
- LRMR N/A
- RDIB 1937
- Country
- LRMR United States
- RDIB United States
- Employees
- LRMR N/A
- RDIB N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- RDIB Movies/Entertainment
- Sector
- LRMR Health Care
- RDIB Consumer Discretionary
- Exchange
- LRMR Nasdaq
- RDIB Nasdaq
- Market Cap
- LRMR 171.6M
- RDIB 140.2M
- IPO Year
- LRMR N/A
- RDIB N/A
- Fundamental
- Price
- LRMR $2.67
- RDIB $9.51
- Analyst Decision
- LRMR Strong Buy
- RDIB
- Analyst Count
- LRMR 7
- RDIB 0
- Target Price
- LRMR $18.86
- RDIB N/A
- AVG Volume (30 Days)
- LRMR 1.1M
- RDIB 6.7K
- Earning Date
- LRMR 08-06-2025
- RDIB 08-13-2025
- Dividend Yield
- LRMR N/A
- RDIB N/A
- EPS Growth
- LRMR N/A
- RDIB N/A
- EPS
- LRMR N/A
- RDIB N/A
- Revenue
- LRMR N/A
- RDIB $205,644,000.00
- Revenue This Year
- LRMR N/A
- RDIB $7.47
- Revenue Next Year
- LRMR N/A
- RDIB $13.22
- P/E Ratio
- LRMR N/A
- RDIB N/A
- Revenue Growth
- LRMR N/A
- RDIB N/A
- 52 Week Low
- LRMR $1.61
- RDIB $5.78
- 52 Week High
- LRMR $11.20
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- LRMR 56.20
- RDIB 45.18
- Support Level
- LRMR $2.60
- RDIB $9.00
- Resistance Level
- LRMR $3.02
- RDIB $12.72
- Average True Range (ATR)
- LRMR 0.25
- RDIB 1.33
- MACD
- LRMR 0.01
- RDIB -0.12
- Stochastic Oscillator
- LRMR 51.35
- RDIB 19.13
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.